These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36739366)

  • 21. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
    Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
    Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
    Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
    Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
    Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
    Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Chiang CL; Chan SK; Lee SF; Choi HC
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
    Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
    Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Murakami S; Inoue T; Kuroyanagi K; Kawamura H; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    J Gastroenterol Hepatol; 2024 Oct; 39(10):2158-2168. PubMed ID: 38943340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year.
    Kim Y; Kim JS; Kang B; Kim I; Kim H; Lee WS; Sang YB; Jung S; An C; Kim C; Chon HJ
    Cancer Res Treat; 2024 Oct; 56(4):1231-1239. PubMed ID: 38810969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
    Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
    Oncologist; 2024 Jul; 29(7):e922-e931. PubMed ID: 38530254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.
    Wang K; Yu HM; Xiang YJ; Cheng YQ; Ni QZ; Guo WX; Shi J; Feng S; Zhai J; Cheng SQ
    Future Oncol; 2022 Sep; 18(30):3367-3375. PubMed ID: 35968836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Yamauchi Y; Saeki I; Yamasaki T; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Nishimura T; Tanabe N; Oono T; Matsumoto T; Ishikawa T; Marumoto Y; Matsukuma S; Shindo Y; Tokumitsu Y; Yoshimine S; Murakami J; Tanaka T; Kimura S; Hoshii Y; Hamano K; Nagano H; Takami T
    Hepatol Res; 2023 Jul; 53(7):681-686. PubMed ID: 36826420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
    Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
    JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study.
    Ishikawa T; Yamazaki S; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Anticancer Res; 2024 Jan; 44(1):361-368. PubMed ID: 38159993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
    Haghnejad V; Muller M; Blaise L; Gerolami R; Bouattour M; Assenat E; Manfredi S; Peron JM; Burcheri-Curatolo A; Lopez A; Ressiot E; Nahon P; Bronowicki JP
    Dig Liver Dis; 2023 Jul; 55(7):938-944. PubMed ID: 37019737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.
    Ai H; Gong T; Ma Y; Ma G; Ding W; Ding W; Wang W; Zhao X
    Front Immunol; 2024; 15():1358602. PubMed ID: 38863699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
    Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma].
    Kaneko Y; Kaneshiro M; Watanabe H
    Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):837-844. PubMed ID: 37821373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.